Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 9/20 | 0.61 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | MMP13 | P45452 | 6/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | TARS1 | P26639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6686715 | 0.89 | MMP13 (0.58) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7354064 | 0.85 | MMP9 (0.69) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL1655863 | 0.82 | ADAMTS4 (0.85) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7354161 | 0.78 | MMP13 (0.56) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7348920 | 0.78 | MMP9 (0.55) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7763645 | 0.78 | MMP9 (0.55) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7347207 | 0.78 | MMP9 (0.55) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL7981017 | 0.76 | SMN1; SMN2 (0.62) | ADAMTS4MMP9MMP13MMP1MMP2 | |
| SCHEMBL8283268 | 0.76 | ADAMTS4 (1.00) | ADAMTS4MMP13MMP2 | |
| SCHEMBL6266743 | 0.75 | MMP9 (0.45) | ADAMTS4MMP9MMP13MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |